---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006451"
form_type: "8-K"
ticker: null
cik: "0001597264"
company_name: "Blueprint Medicines Corp"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:31:18.347071+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Blueprint Medicines Q1 AYVAKIT revenue $92.5M, raises full-year guidance to $390-410M

## Summary
- AYVAKIT net product revenue $92.5M in Q1 2024, up >135% YoY from $39.1M.
- Full-year AYVAKIT revenue guidance raised to $390-410M from prior $360-390M.
- Net income of $89.1M includes a $173.7M non-cash debt extinguishment gain; prior year net loss $129.6M.
- Cash, cash equivalents and investments $735.6M as of March 31, 2024, down from $767.2M at year-end 2023.
- BLU-808 IND on track for Q2 2024; BLU-222 combination data to be presented at ASCO 2024.

## SEC filing metadata
- accession: 0001558370-24-006451
- form_type: 8-K
- cik: 0001597264
- company_name: Blueprint Medicines Corp
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1597264/000155837024006451/0001558370-24-006451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1597264/000155837024006451/bpmc-20240502x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006451
- JSON: https://secwatch.observer/filing/0001558370-24-006451.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006451.txt

## Key facts
- Earnings Releases
  Blueprint Medicines Corp reported the first quarter ended March 31, 2024 results: revenue $92.5 million. Guidance raised.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $92.5 million
  - Guidance: raised
  - Result: reported results
  source text: -- Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 -- -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues --
  evidence_url: https://www.sec.gov/Archives/edgar/data/1597264/000155837024006451/0001558370-24-006451-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.